紫蓝方加味联合阿维A胶囊及卡介菌多糖核酸治疗扁平疣疗效观察  被引量:3

Efficacy of Zilan Decoction combined with acitretin and BCG-polysaccharide nucleic acid in treatment of verruca plana

在线阅读下载全文

作  者:陈伟[1] 罗卫[2] 杨丽红[3] 

机构地区:[1]武警北京总队第三医院皮肤科,100141 [2]空军总医院皮肤科,北京100036 [3]武警北京总队第三医院理疗科,100141

出  处:《武警医学》2012年第6期489-491,共3页Medical Journal of the Chinese People's Armed Police Force

摘  要:目的观察应用紫蓝方加味口服和外洗联合阿维A胶囊及卡介菌多糖核酸注射液治疗扁平疣的效果。方法将108例扁平疣患者随机分2组,治疗组56例,予以口服和外用紫蓝方,同时联合阿维A胶囊及卡介菌多糖核酸注射液治疗;对照组52例,仅予以紫蓝方内服和外洗。4周后进行疗效评定和对比。结果治疗组痊愈率89.29%,总有效率96.43%,对照组痊愈率和总有效率分别为69.23%,82.69%。二者比较差异均有统计学意义(χ2=6.69,P<0.05;χ2=5.56,P<0.05)。结论紫蓝方加味内服和外洗联合阿维A胶囊及卡介菌多糖核酸注射液治疗扁平疣疗效确切。Objective To study the clinical efficacy of Zilan Decoction combined with acitretin and BCG - polysaccharide nucleic acid in the treatment of verruca plana. Methods One hundred and eight patients with verruca plana were randomly divided into two groups:the treatment group (56 patients)and the control group (52 patients). Zilan Decoction combined with acitretin and BCG - polysaecharide nucleic acid were given to the treatment group while the control group was treated with Zilan Decoction alone. Four weeks later, the therapeutic efficacy was analyzed after completion of the therapy. Results The curative rate was 89.29% in the treatment group and 69.23% in the control group. The total effective rate was 96.43% in the treatment group and 82.69% in the control group. There was statistically significant difference in the curative rate and total effective rate between the two groups. The results of statistics for the two groups were X^2= 6.69, P 〈 0.05 and X^2 = 5.56, P 〈 0.05, separately. Conclusions Zilan Decoction combined with acitretin and BCG - polysaceharide nucleic acid phototherapy is more effective than Zilan Decoction alone in the treatment of verruca plana.

关 键 词:扁平疣 紫蓝方 阿维A胶囊 卡介菌多糖核酸注射液 

分 类 号:R752.51[医药卫生—皮肤病学与性病学]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象